16h
GlobalData on MSNAlltrna plans to tackle rare diseases using tRNA-based therapiesAlltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.
A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...
A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results